Cartesian Therapeutics, Inc. RNAC
Cartesian Therapeutics, Inc. (Nasdaq: RNAC) is a CNS/neurology/psychiatry drug developer. Its lead program, Descartes-08, is in Phase 3 for Myasthenia gravis. Its next catalyst on record is Descartes-08: Topline data from Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in first quarter of 2027. (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Descartes-08 — Topline data from Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in first quarter of 2027. (Q1 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Descartes-08 | Myasthenia gravis (AURORA) | cell therapy | Phase 3 |
| Descartes-08 | Dermatomyositis (TRITON) | cell therapy | Phase 2 |
Recent results and decisions
- Sep 29, 2026positive Retreatment of 5 MG patients gave mean MG-ADL reduction of 6.6 points at Month 12; no new safety signals, no CRS or ICANS.
Retreated patients observed an average MG-ADL reduction of 6.6 (±4.2) points from baseline at Month 12.
Filing - Apr 30, 2026started Phase 2 TRITON trial of Descartes-08 in myositis initiated.
Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome initiated
Filing - Jan 9, 2026accepted FDA accepted the IND for the planned Phase 2 myositis trial of Descartes-08.
Today, Cartesian announced the U.S. Food and Drug Administration (FDA) accepted the investigational new drug (IND) application for its planned Phase 2 trial in myositis.
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.